Anti-SARS-CoV-2 IgA Identifies Asymptomatic Infection in First Responders. Academic Article uri icon

Overview

abstract

  • BACKGROUND: Immunoglobulin A (IgA) is an important component of the early immune response to SARS-CoV-2. Prior serosurveys in high-risk groups employing IgG testing alone have provided discordant estimates. The potential added benefit of IgA in serosurveys has not been established. METHODS: Longitudinal serosurvey of first responders (police, emergency medical service providers, fire fighters, and other staff) employing 3 serologic tests (anti-spike IgA, anti-spike IgG, and anti-nucleocapsid IgG) correlated with surveys assessing occupational and nonoccupational risk, exposure to COVID-19, and illnesses consistent with COVID-19. RESULTS: Twelve percent of first responders in Colorado at baseline and 22% at follow-up were assessed as having SARS-CoV-2 infection. Five percent at baseline and 6% at follow-up were seropositive only for IgA. Among those IgA positive only at baseline, the majority (69%) had a positive antibody at follow-up; 45% of those infected at baseline and 33% at follow-up were asymptomatic. At all time points, the estimated cumulative incidence in our study was higher than that in the general population. CONCLUSIONS: First responders are at high risk of infection with SARS-CoV-2. IgA testing identified a significant portion of cases missed by IgG testing and its use as part of serologic surveys may improve retrospective identification of asymptomatic infection.

publication date

  • February 15, 2022

Research

keywords

  • Antibodies, Viral
  • Asymptomatic Infections
  • COVID-19
  • Emergency Responders
  • Immunoglobulin A

Identity

PubMed Central ID

  • PMC8549282

Scopus Document Identifier

  • 85124632834

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiab524

PubMed ID

  • 34636907

Additional Document Info

volume

  • 225

issue

  • 4